Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib Study of AZD9150 in Advanced/Metastatic Hepatocellular Carcinoma
jRCT2080222157Phase 1
- Sponsor
- AstraZeneca
- Start
- Jul 2013
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danvatirsen in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD9150, Pharmacokinetics of AZD9150 and 1 more.
02
Drugs
danvatirsen
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080222157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222157.